Items where authors include "Challagulla, S."
![[up]](/style/images/multi_up.png)
Up a levelArticle
Shah, B., Challagulla, S., Xu, S. et al. (7 more authors) (2025) Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leukemia & Lymphoma, 66 (12). pp. 2238-2248. ISSN 1042-8194
Proceedings Paper
Shah, B., Challagulla, S., Xu, S. et al. (5 more authors) (2024) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). In: Clinical Lymphoma Myeloma and Leukemia. Society of Hematologic Oncology 2024 Annual Meeting, 04-07 Sep 2024, Houston, Texas, USA. Elsevier BV , S227-S227.
Shah, B., Challagulla, S., Xu, S. et al. (5 more authors) (2024) MCL-509 Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). In: Clinical Lymphoma Myeloma and Leukemia. Society of Hematologic Oncology 2024 Annual Meeting, 04-07 Sep 2024, Houston, Texas. Elsevier BV , S516-S517.